New Silk Road Capital
新丝路资本
New Silk Road Capital (新丝路资本) is a Chinese investment fund that appears as a co-investor in early-to-growth stage tech and healthcare deals. The bundle shows it participating as a follower in at least two rounds: DeepWise's nearly RMB 100 million Series C1 in late 2021, an AI ultrasound company, and DigiSight Medical's multi-million-yuan Pre-A+ round in mid-2023, a Hangzhou-based ophthalmic surgical robotics firm . Beyond these two deals, elsewhere's corpus does not contain further information on its founding, team, AUM, or investment thesis.
AI-generated — may contain errors, please verify.
Coverage
Linear Capital's Pre-A lead portfolio company **DigiSight Medical** has closed a multi-million-yuan Pre-A+ round, with existing investor Linear Capital continuing to back the company.
Accelerating clinical trials and R&D for ophthalmic and microsurgical robotic products.
线性资本·2022, the Door Opens to the Future | 5Y News Monthly
The big news from last month.
五源资本·5Y News | 5Y Capital Portfolio Company Deepwise Completes Nearly RMB 100 Million Series C1 Funding Round
Bringing AI medical imaging into grassroots healthcare.
五源资本·
